WO2019066389A1 - Protéine de fusion nc comprenant un fragment de domaine n-terminal et un fragment de domaine c-terminal de la protéine de nucléocapside du coronavirus du srmo, et kit de diagnostic d'une infection à coronavirus du srmo utilisant ladite protéine de fusion nc - Google Patents

Protéine de fusion nc comprenant un fragment de domaine n-terminal et un fragment de domaine c-terminal de la protéine de nucléocapside du coronavirus du srmo, et kit de diagnostic d'une infection à coronavirus du srmo utilisant ladite protéine de fusion nc Download PDF

Info

Publication number
WO2019066389A1
WO2019066389A1 PCT/KR2018/011155 KR2018011155W WO2019066389A1 WO 2019066389 A1 WO2019066389 A1 WO 2019066389A1 KR 2018011155 W KR2018011155 W KR 2018011155W WO 2019066389 A1 WO2019066389 A1 WO 2019066389A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
mers
terminal domain
cov
amino acid
Prior art date
Application number
PCT/KR2018/011155
Other languages
English (en)
Korean (ko)
Inventor
정대균
윤선우
김혜권
송대섭
노지영
안민주
Original Assignee
한국생명공학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국생명공학연구원 filed Critical 한국생명공학연구원
Publication of WO2019066389A1 publication Critical patent/WO2019066389A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Definitions

  • NC fusion protein including an N-terminal domain fragment and a C-terminal domain fragment of a nucleocapsid protein of a mers coronavirus and a kit for diagnosing a mers coronavirus infection using the same
  • the present invention relates to an NC fusion protein including an N-terminal domain fragment and a C-terminal domain fragment of a mucin coronavirus nucleocapsid protein, and a kit for diagnosing a mors coronavirus infection using the same.
  • MERS coronavirus (MERS coronavius, MERS_CoV) is a newly discovered new beta coronavirus in Saudi Arabia in 2012 (Azhar EI, et al., 2014).
  • the name of the MERS-CoV was named by the International Virus Classification Commission in May 2013 and was formerly called the new coronavirus, SARS-like virus, Middle Eastern SARS, or Saudi SARS.
  • This infection pathway of MERS-CoV is known to be transmitted from camels to humans and camels.
  • MERS-CoV is transmissible to humans and has a mortality rate of 40%.
  • MERS-CoV The genome of MERS-CoV is non-segmented and encodes 11 proteins of approximately 30 kb in size.
  • the eleven proteins consist of two replicating polyproteins, four structural proteins, and five non-structural proteins.
  • MERS-CoV Ag Test product is currently in use in Saudi Arabia and the United Arab Emirates for the diagnosis of camel mers.
  • MERS which has a high mortality rate, is associated with complications such as pneumonia or acute renal failure as well as respiratory infection, so early treatment through rapid diagnosis is very important.
  • MERS rapid diagnostic kit approved for human use development is necessary.
  • Another object of the present invention is to provide a kit for the diagnosis of MERS-CoV infection capable of diagnosing MERS-CoV containing the antigen.
  • the present invention provides a fusion protein comprising an N- terminal domain fragment and a c- terminal domain fragment of a nucleocapsid protein of MERS-CoV (hereinafter,
  • the present invention provides a monoclonal antibody that specifically binds to an NC fusion protein of a nucleocapsid protein of MERS-CoV.
  • the present invention provides an expression vector comprising a nucleotide encoding an NC fusion protein of a nucleocapsid protein of MERS-CoV.
  • the present invention also provides a host cell transfected with said expression vector.
  • the present invention also provides a method for producing an NC fusion protein comprising the step of obtaining an NC fusion protein from said transfected host cell.
  • step (A) inducing an immune response by injecting an NC fusion protein of a nucleocapsid protein of MERS-CoV as an antigen into an experimental animal; And (b) recovering the antibody from the animal of step (a).
  • the present invention provides a nucleoside- A kit for the diagnosis of MERS-CoV infection comprising NC fusion protein of protein.
  • the present invention provides a method for providing MERS-CoV infection information comprising the step of adding a sample isolated from a subject to a diagnosis kit for MERS-CoV infection.
  • NC fusion protein of nucleoscope protein of MERS-CoV represented by SEQ ID NO: 8 can be mass-produced in E. coli.
  • the antibody specifically binds to an antibody of MERS-CoV produced in an individual and can be widely used for MERS-CoV diagnosis.
  • Fig. 1 shows an E. coli expression vector pET28a-MERS-CoV-NP_NC capable of expressing an NC fusion protein.
  • FIGS. 2A to 2C show the results of confirming the N-terminal domain (a), the C-terminal domain (b) and the NC fusion protein domain (c) using SDS-PAGE.
  • Sup is a supernatant
  • ppt is a pellet
  • FT is a low through
  • HS-W is a high salt wash
  • 73 ⁇ 4) -W is a 7% imidazole wash.
  • Figure 2d shows the results of SDS-PAGE analysis of N-terminal, C-terminal, and NC fusion proteins purified by nickel-affinity chromatography.
  • 5 ug means the amount of each protein loaded.
  • FIG. 3 shows the result of ELISA test for confirming the effect of NC fusion protein on the immune antibody formation using a mouse.
  • 0D means the absorbance (opt i cal dens i ty).
  • FIG. 4 is a graph comparing detection sensitivities of a kit using a conventional MERS-CoV diagnostic kit, euroi ⁇ flour, and a kit using the NC fusion protein of the present invention.
  • FIG. 5 shows the results of purification by NC fusion protein chromatography of MERS-CoV, SARS-CoV, HCoV-229E and HCoV-0C43 proteins and SDS-PAGE.
  • 5 ug means the amount of each protein loaded.
  • Figure 6 shows the cross reactivity of MERS-CoV, SARS-CoV, HCoV-229E and HCoV-0C43 proteins with human CoV antibodies.
  • the present invention provides a fusion protein of an N-terminal domain fragment and a C-terminal domain fragment of a nucleocapsid protein of a mi ddle east respiratory syndrome (MERS) coronavirus.
  • MERS east respiratory syndrome
  • the nucleocapsid of the above-mentioned Mers coronavirus (hereinafter referred to as MERS-CoV) is composed of a total of 11 proteins (two repetitive proteins, four structural proteins, and five nonstructural proteins) encoded by the MERS genome, . These nucleocapsids serve to protect the genetic material when the MERS-CoV is extracellular and to help the gene enter the cell when it penetrates into new host cells.
  • the N-terminal domain of the nucleocapsid protein of MERS-CoV may be a polypeptide having the amino acid sequence of SEQ ID NO: 4.
  • the protein may be encoded by the nucleotide sequence of SEQ ID NO: 3.
  • the fragment of the N-terminal domain has 1 to 134, 10 to 120, 30 to 100, or 50 of the amino acid sequence from amino acid position 36 to 169 of SEQ ID NO: To 80 contiguous amino acid sequences.
  • the C-terminal domain of the nucleocapsid protein of MERS-CoV may be a polypeptide having the amino acid sequence of SEQ ID NO: 6.
  • the protein may be encoded by the nucleotide sequence of SEQ ID NO: 5.
  • the fragment of the C-terminal domain has 1 to 117, 10 to 100, 20 to 80, or 30 of the amino acid sequence from amino acid position 246 to 362 of SEQ ID NO: To 50 contiguous amino acid sequences.
  • the NC fusion protein of the nucleocapsid protein of MERS-CoV may have the amino acid sequence of SEQ ID NO: 8.
  • the NC fusion protein can be encoded by the nucleotide sequence of SEQ ID NO: 7.
  • the present invention provides a monoclonal antibody that specifically binds to a fusion protein comprising an N-terminal domain fragment and a C-terminal domain fragment of a nucleocapsid protein of MERS-CoV.
  • antibody 1 &quot is a component produced by the stimulation of an antigen in the immune system and specifically binds to a specific antigen to migrate lymph and blood It is a protein that causes antigen-antibody reaction.
  • the antigen-antibody reaction has a high specificity for each antigen.
  • the antibody produced by the specific antigen does not, in principle, counteract with other antigens.
  • Such high specificity is used in immunoassays, allergy, various diseases, and in the determination of types and types of infectious viruses.
  • the vector may be pET28a, and the transformant may be an Escherichia microorganism.
  • the amino acid residue 36-169 of the N-terminal domain of the MERS-CoV nucleocapsid protein of SEQ ID NO: 4 is subcloned into the NdeI and BamHI sites of the pET28a vector and overexpressed Respectively.
  • amino acid residues 246-362 of the C-terminal domain of the MERS-CoV nucleocapsid protein shown in SEQ ID NO: 6 were subcloned into EcoRI and Xhol sites of pET28a and overexpressed using E. coli strain. Then, each protein was inoculated into E. coli and cultured. ,
  • antigen &quot is a protein that expresses a virus as a component capable of inducing immunological function among components of the virus.
  • MERS-CoV nucleocapsid protein having the amino acid sequence of SEQ ID NO: Of the NC fusion protein domain acted as an antigen to induce immune antibody formation when administered to an individual.
  • the present invention also provides an expression vector comprising a nucleotide encoding said fusion protein, wherein said host cell transfected with said expression vector is provided.
  • the present invention also provides a method for producing an NC fusion protein comprising the step of obtaining an NC fusion protein from said transfected host cell.
  • NC fusion proteins were obtained by subcloning the nucleotides encoding the N-terminal and C-terminal domains of the MERS-CoV nucleocapsid proteins in a pET28a vector and inoculating them into E. coli.
  • the present invention provides a kit for the diagnosis of MERS-CoV infection comprising an NC fusion protein of a nucleocapsid protein of MERS-CoV.
  • the NC fusion protein of the MERS-CoV nucleocapsid protein having the amino acid sequence of SEQ ID NO: 8 can specifically bind to the antibody against the mers coronavirus, and thus the MERS-CoV infection diagnostic kit Lt; / RTI > Induced antigen-antibody reaction, MERS-CoV infection could be diagnosed effectively as a low-concentration antigen as compared with the existing MERS-CoV infection diagnostic kit.
  • the antibody generated from an individual infected with MERS-CoV can bind to the NC fusion protein of the present invention, so that it is possible to easily diagnose whether the individual has been infected with MERS-CoV.
  • the present invention provides a method for providing a mers coronavirus infection information, comprising the step of adding a sample isolated from a subject to a diagnosis kit for MERS-CoV infection.
  • MERS-CoV infection detection kit &quot is a kit for rapidly diagnosing MERS-CoV infection and diseases caused therefrom.
  • a strip coated with an antigen on a specimen This kit can be used to detect the test results within 10 to 15 minutes and does not require any equipment or diagnostic equipment to make it easy for anyone to easily detect MERS-CoV infection Which can be diagnosed by the disease.
  • the above-mentioned " disease caused by Mers-Coronavirus infection" may be a respiratory disease. Severe respiratory symptoms such as a high temperature of 38 0 C or more, coughing or shortness of breath may occur after a latency period of 2 to 14 days after the virus infection . Diarrhea, or constipation. In the case of a chronic disease or immunodeficiency, the complication of pneumonia or acute renal failure may accompany death. DETAILED DESCRIPTION OF THE INVENTION
  • Example 1 MERS- € oV nucleocapsid NC-NC with N-terminal and C- Preparation of fusion protein
  • the structure of the nucleocapsid protein was analyzed.
  • the amino acid sequence of the nucleocapsid protein having a stable form of the secondary structure was determined through the above structural analysis.
  • the synthesis of the nucleocapsid protein (413 amino acids) of MERS-CoV was carried out in bioneer, and the nucleotide sequence thereof was shown in SEQ ID NO: 1.
  • Terminal domain of the MERS-CoV nucleocapside protein shown in SEQ ID NO: 4 in order to prepare a nucleocapsid fusion protein comprising the N-terminal and C-terminal domain fragments of the nucleocapsid protein, 169 were subcloned into the Ndel and BamHI sites of the pET28a vector and overexpressed with nucleotides encoding the 36-169 portion of the N-terminus using the Escherichia coli BL2KDE3) pLysS Rosetta) strain.
  • a nucleotide encoding amino acid residues 246-362 of the C-terminal domain represented by SEQ ID NO: 6 as another site of the nucleocapsid protein was subcloned into the EcoRI and Xhol sites of pET28a and Escherichia coli BL21 (DE3) pLysS Rosetta) was used to overexpress the nucleotides encoding the 246-362 portion of the C-terminus.
  • nucleotides encoding the N-terminal 36-169 and the nucleotides encoding the 246-362 portion of the C-terminal were introduced into the pET28a vector, respectively, Ndel / BamHI and EcoRI / Xh.
  • IPTG (i sopropyl ⁇ -D-1-hi ogalacty anos i de) reagent was added and cultured at 291K for 18 hours.
  • the E. coli expression vector pET28a-MERS-CoV_NP_NC used above is shown in Fig.
  • the Hi s-tagged N-terminal, C-terminal and NC fusion proteins were first purified by nickel-affinity chromatography. NC fusion protein was purified once more by HiPrep 16/60 Sephacryl S-200 HR gel-filtration chromatography using phosphate buffered saline (PBS) at 2-fold concentration. Through the above procedure, purified N-terminal, C-terminal and NC fusion protein domains were obtained. The results are shown in Fig.
  • the N-terminal domain (a), the C-terminal domain (b) And NC fusion protein domain (c) were identified on SDS-PAGE. Further, as shown in Fig. 2 (d), each of the domains was purified by chromatography to a purity of 95% or more. At this time, the nucleotide sequence of the NC fusion protein domain is shown in SEQ ID NO: 7, and the 276 amino acid sequences thus prepared are shown in SEQ ID NO: 8.
  • Experimental Example 1 Confirmation of Antibody Production of NC Fusion Protein
  • a pre-immune serum was collected and used as a negative control group before injecting the purified NC fusion protein domain antigen into a mouse (Coatech, Korea).
  • primary immunization Pr imary i un uni ze
  • 100 ug of antigen were co-injected with Freund's adjuvant and injected intramuscularly into 4 mice, respectively, and 2 weeks later with Freund's adjuvant, Car boosting was carried out.
  • primary blood was collected and subjected to ELISA test and secondary boosting.
  • each mouse was bled and the final serum was separated and subjected to a final ELISA test. At this time, in the ELISA test, 100 ng of antigen was used per well (wel l).
  • the immunized serum was diluted 1: 100 to 1: 1, 000, 000 by 1XPBS, and anti-mouse IgG-HRP (ABC5001) was diluted at a ratio of 1: 5,000 for secondary confirmation.
  • the color development was detected at an optical density of 405 nm using an ELISA reader, and finally, immunological antibody production was confirmed, which is shown in FIG.
  • NC fusion protein showed the effect of forming an immune antibody in all four mice used in the above experiment. This means that the NC fusion protein domain can act as an antigen in the individual and effectively induce the antibody. As a result, it was confirmed that NC fusion protein can be used as an antigen to prepare an antibody for diagnosis of MERS-CoV infection.
  • Experimental Example 2 Comparison of diagnostic performance of MERS ⁇ CoV diagnostic kit and commercial kit developed using NC fusion protein
  • the superiority of the MRS-CoV diagnostic kit developed using the NC fusion protein prepared in Example 1 was compared with the commercially available MERS-CoV diagnostic kit.
  • ELISA was performed on a plate coated with 400 ng of NC fusion protein antigen on a 40-fold plate of human serum.
  • Secondary antibody HRP-conjugated goat anti-human IgG was diluted 1: 100 ug / ml) and subjected to an indirect ELISA.
  • MERS-CoV diagnostic kit As a commercially available MERS-CoV diagnostic kit, a kit from euroimmun was used. ELISA was performed according to the manufacturer's manual using human serum on the plate coated with the antigen contained in the kit. ELISA was performed by diluting human serum with a sample buffer at a ratio of 1: 100 to the plate contained in the kit according to the manufacturer's protocol Respectively. The results are shown in Fig.
  • the MERS-CoV diagnostic kit manufactured using the plate coated with the NC fusion protein antigen showed a diagnostic ability four times higher than that of the commercially available MERS-CoV kit . This means that the MERS-CoV diagnostic kit using plates coated with NC fusion protein antigens can be effectively diagnosed at the early stage or at the recovery stage of MERS-CoV infection even in a patient having a low amount of virus in the body.
  • Experimental Example 3 Cross-reactivity determination of human CoV NC fusion protein antibody
  • SARS-CoV SARS-CoV
  • HCoV-229E SARS-CoV
  • HCoV_0C43 nucleocapsid proteins were prepared via an E. coli expression system.
  • the SARS-CoV nucleocapsid protein may be a polypeptide having the amino acid sequence of SEQ ID NO: 9, and the protein may be encoded by the nucleotide sequence of SEQ ID NO: 10.
  • the HCoV-229E nucleocapsid protein may be a polypeptide having the amino acid sequence of SEQ ID NO: 11, and the protein may be encoded by the nucleotide sequence of SEQ ID NO:
  • the HCoV-0C43 nucleocapsid protein may be a polypeptide having the amino acid sequence of SEQ ID NO: 13, and the protein may be encoded by the nucleotide sequence of SEQ ID NO: 14.
  • each human CoV nucleocapsid protein was subcloned into the Ndel and BamHI sites of the pET28a vector, and each human CoV nucleocapsid protein was overexpressed using Escherichia coli BL2KDE3 pLysS Rosetta strain.
  • the method of overexpressing and purifying each of the human CoV nucleocapsid proteins is described in detail in Example 1 The same procedure was followed. Through the above process, purified NC fusion protein domains of SARS-CoV, HCoV-229E and HCoV_0C43 nucleocapsid proteins were obtained, and the results are shown in FIG.
  • the NC fusion protein of the MERS-CoV, SARS-CoV, HCoV-229E and HCoV-0C43 proteins obtained in Experimental Example 3.1 caused cross-reactivity with the human CoV antibody.
  • the monoclonal antibody used in the 96-well plate surface coating was an N-terminal specific antibody of the MERS-CoV nucleocapsid protein and coated at a concentration of 100 ng / well at 4 ° C and 0 / N coating. Coated 96-well plates were washed once with PBST buffer and then blocked with 2% BSA at 37 ° C for 1 hour.
  • the purified MERS-CoV, SARS-CoV, HCoV-229E and HCoV_0C43 nucleocapsid recombinant proteins were incubated at 100 ng / well to 0.8. ng / well and incubated at 37 [ deg.] C for 2 hours. Subsequently, the cells were washed three times for 5 minutes each with PBST. HRP-conjugated MERS-CoV nucleocapsid C-terminal specific mAb was treated at a concentration of 200 ng / well and incubated at 37 ° C for 1 hour. Then, the cells were washed five times with PBST for 5 minutes each, and then subjected to color reaction with ECL solution. The results are shown in FIG.
  • the MERS-CoV nucleocapside NC fusion protein has cross-reactivity with human CoV antibodies This was done well. This means that the antibody can be used as an antibody to diagnose MERS-CoV.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne : une protéine de fusion NC comprenant des fragments de domaine N-terminal et C-terminal d'une protéine de nucléocapside du coronavirus du SRMO ; et un kit de diagnostic d'une infection à coronavirus du SRMO utilisant ladite protéine de fusion NC. Une protéine de fusion NC selon la présente invention peut être produite en masse, dans E coli, de manière beaucoup plus stable qu'une protéine de nucléocapside pleine longueur. De plus, selon la présente invention, lorsque la protéine de fusion NC représentée par SEQ ID NO : 8 est utilisée en tant qu'antigène, un anticorps spécifique du coronavirus du SRMO peut être efficacement produit. En outre, étant donné que la protéine de fusion NC réagit avec un anticorps induit par le coronavirus du SRMO, la protéine de fusion NC peut être utilisée dans un kit de diagnostic du coronavirus du SRMO.
PCT/KR2018/011155 2017-09-26 2018-09-20 Protéine de fusion nc comprenant un fragment de domaine n-terminal et un fragment de domaine c-terminal de la protéine de nucléocapside du coronavirus du srmo, et kit de diagnostic d'une infection à coronavirus du srmo utilisant ladite protéine de fusion nc WO2019066389A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0124394 2017-09-26
KR20170124394 2017-09-26

Publications (1)

Publication Number Publication Date
WO2019066389A1 true WO2019066389A1 (fr) 2019-04-04

Family

ID=65902713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011155 WO2019066389A1 (fr) 2017-09-26 2018-09-20 Protéine de fusion nc comprenant un fragment de domaine n-terminal et un fragment de domaine c-terminal de la protéine de nucléocapside du coronavirus du srmo, et kit de diagnostic d'une infection à coronavirus du srmo utilisant ladite protéine de fusion nc

Country Status (2)

Country Link
KR (1) KR102103857B1 (fr)
WO (1) WO2019066389A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111323511A (zh) * 2020-03-26 2020-06-23 浙江大学医学院附属第四医院(浙江省义乌医院、浙江大学医学院附属第四医院医共体) 一种用于灭活新冠病毒的快速检测试剂盒及方法
CN112920278A (zh) * 2021-02-18 2021-06-08 青岛硕景生物科技有限公司 一种新型冠状病毒特异性融合蛋白抗原及其制备方法和应用
WO2021219121A1 (fr) * 2020-04-30 2021-11-04 养生堂有限公司 Réactif de détection pour le criblage d'un agent de blocage d'infections à coronavirus, et procédé de détection
WO2021231560A1 (fr) * 2020-05-12 2021-11-18 Greffex, Inc. Protéines de spicule de coronavirus d'ingénierie utilisées en tant qu'antigènes de vaccin, leur conception et leurs utilisations
WO2022038499A1 (fr) * 2020-08-17 2022-02-24 Grifols Diagnostic Solutions Inc. Protéines de fusion comprenant des domaines nucléocapsidiques du sars-cov-2
CN114702555A (zh) * 2022-03-09 2022-07-05 中国计量科学研究院 新型冠状病毒核衣壳蛋白（n蛋白）的制备和定值方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111505277A (zh) * 2020-03-10 2020-08-07 四川省人民医院 2019新型冠状病毒IgG抗体检测试剂盒
KR102313941B1 (ko) * 2020-05-04 2021-10-18 대한민국 Covid-19 감염 진단을 위한 rt-lamp용 키트 및 방법
KR102613962B1 (ko) * 2020-09-07 2023-12-18 주식회사 지아이셀 코로나바이러스 유래 수용체 결합 도메인 및 뉴클레오캡시드 단백질을 포함하는 융합단백질 및 이의 용도
CN112505330B (zh) * 2020-11-09 2024-03-29 昆明市妇幼保健院 基于核衣壳蛋白的融合蛋白的新型冠状病毒检测的试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101593641B1 (ko) * 2014-11-17 2016-02-12 주식회사 바이오노트 중동호흡기증후군 코로나바이러스 뉴클레오캡시드를 인식하는 항체 및 그의 용도
EP3045181A1 (fr) * 2015-01-19 2016-07-20 Ludwig-Maximilians-Universität München Nouveau vaccin contre le coronavirus du syndrome respiratoire du moyen orient (MERS-CoV)
US20160264647A1 (en) * 2013-10-18 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
US20160296617A1 (en) * 2013-03-01 2016-10-13 New York Blood Center, Inc. Immunogenic Composition for MERS Coronavirus Infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160296617A1 (en) * 2013-03-01 2016-10-13 New York Blood Center, Inc. Immunogenic Composition for MERS Coronavirus Infection
US20160264647A1 (en) * 2013-10-18 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
KR101593641B1 (ko) * 2014-11-17 2016-02-12 주식회사 바이오노트 중동호흡기증후군 코로나바이러스 뉴클레오캡시드를 인식하는 항체 및 그의 용도
EP3045181A1 (fr) * 2015-01-19 2016-07-20 Ludwig-Maximilians-Universität München Nouveau vaccin contre le coronavirus du syndrome respiratoire du moyen orient (MERS-CoV)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEN, Y.: "A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein", EMERGING MICROBES & INFECTIONS, vol. 6, 24 May 2017 (2017-05-24), pages e37, XP055586083 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111323511A (zh) * 2020-03-26 2020-06-23 浙江大学医学院附属第四医院(浙江省义乌医院、浙江大学医学院附属第四医院医共体) 一种用于灭活新冠病毒的快速检测试剂盒及方法
WO2021219121A1 (fr) * 2020-04-30 2021-11-04 养生堂有限公司 Réactif de détection pour le criblage d'un agent de blocage d'infections à coronavirus, et procédé de détection
WO2021231560A1 (fr) * 2020-05-12 2021-11-18 Greffex, Inc. Protéines de spicule de coronavirus d'ingénierie utilisées en tant qu'antigènes de vaccin, leur conception et leurs utilisations
WO2022038499A1 (fr) * 2020-08-17 2022-02-24 Grifols Diagnostic Solutions Inc. Protéines de fusion comprenant des domaines nucléocapsidiques du sars-cov-2
CN112920278A (zh) * 2021-02-18 2021-06-08 青岛硕景生物科技有限公司 一种新型冠状病毒特异性融合蛋白抗原及其制备方法和应用
CN112920278B (zh) * 2021-02-18 2022-06-28 青岛硕景生物科技有限公司 一种新型冠状病毒特异性融合蛋白抗原及其制备方法和应用
CN114702555A (zh) * 2022-03-09 2022-07-05 中国计量科学研究院 新型冠状病毒核衣壳蛋白（n蛋白）的制备和定值方法
CN114702555B (zh) * 2022-03-09 2023-01-03 中国计量科学研究院 新型冠状病毒核衣壳蛋白n蛋白的制备和定值方法

Also Published As

Publication number Publication date
KR102103857B1 (ko) 2020-04-27
KR20190035542A (ko) 2019-04-03

Similar Documents

Publication Publication Date Title
WO2019066389A1 (fr) Protéine de fusion nc comprenant un fragment de domaine n-terminal et un fragment de domaine c-terminal de la protéine de nucléocapside du coronavirus du srmo, et kit de diagnostic d'une infection à coronavirus du srmo utilisant ladite protéine de fusion nc
CN111269313B (zh) 一种用于检测新型冠状病毒的单克隆抗体及其制备试剂盒的用途
CN111239394B (zh) 一种基于混合抗原快速检测新型冠状病毒抗体试剂盒
EP3855186B1 (fr) Procédé permettant de déterminer l'efficacité d'un vaccin
EP4119575A1 (fr) Épitope d'anticorps dirigé contre la protéine structurelle du sras-cov-2, anticorps réagissant avec l'épitope, procédé de détection de sras-cov-2 à l'aide d'anticorps, kit de détection pour anticorps contenant sras-cov-2, procédé de détection d'anticorps anti-sras-cov-2 contenant un polypeptide d'épitope, kit de détection pour un anticorps anti-sras-cov-2 contenant un polypeptide d'épitope, vaccin contre sras-cov-2 contenant un polypeptide d'épitope, et agent thérapeutique pour une infection à sras-cov-2 contenant l'anticorps
US10948490B1 (en) Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
CN110616192B (zh) 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用
CN112961222B (zh) 2019新型冠状病毒n蛋白线性表位肽和单克隆抗体及应用
CN111748033B (zh) 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒
CN112094326B (zh) 一种新冠病毒抗原及其应用
CN111440228B (zh) 多种亚型流感病毒ha2蛋白共同抗原表位、抗体、鉴定方法和应用
US20210311054A1 (en) Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
CN113416245A (zh) 一种可结合SARS-CoV-2病毒RBD蛋白的中和抗体及其应用
CN110914685A (zh) Rep蛋白作为蛋白质抗原用于诊断试验
JP7159229B2 (ja) 診断アッセイで使用するための改善されたｒｅｐタンパク質
CN114702578A (zh) 新型冠状病毒Omicron突变株特异性抗体及其应用
CN101085812A (zh) 一种sars冠状病毒多肽抗原及其应用
KR102709435B1 (ko) SARS-CoV-2 특이적 신규 항체를 이용한 SARS-CoV-2의 검출방법
KR20130088845A (ko) 인간 사이토메갈로 바이러스 감염의 검출 방법
CN116284352A (zh) 牛白血病病毒抗体及检测试剂盒
CN107739402A (zh) 一种猪瘟病毒Erns蛋白的抗原表位、抗体的制备及应用
WO2021209925A1 (fr) Test sérologique de coronavirus
KR102021537B1 (ko) 황열 바이러스 감염 진단용 신속진단키트 및 이를 이용한 황열 바이러스 검출방법
CN111349637A (zh) 山羊支原体山羊肺炎亚种特异性蛋白及间接elisa试剂盒
CN110078820A (zh) 牛白血病病毒抗体及检测试剂盒

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18860762

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18860762

Country of ref document: EP

Kind code of ref document: A1